SCHEMBL4489874

SCHEMBL4489874

CN(C)C(=O)c1c2c(c(O)c(=O)n1CC#N)C(=O)N(Cc1ccc(F)c(Cl)c1)CC2

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.35
TNIK Q9UKE5 1/20 0.32
HDAC1 Q13547 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
HTR2A P28223 1/20 0.31
GRM2 Q14416 1/20 0.31
PDE5A O76074 1/20 0.31
EGFR P00533 1/20 0.31
PIK3CA P42336 1/20 0.31
MAPK1 P28482 1/20 0.30
FSCN1 Q16658 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489034 0.92 AKR1B1 (0.38) AKR1B1HDAC1HDAC6HTR2AGRM2
SCHEMBL6032265 0.92 AKR1B1 (0.35) AKR1B1HDAC1HDAC6HTR2AGRM2
SCHEMBL4490977 0.90 AKR1B1 (0.42) AKR1B1
SCHEMBL4483837 0.89 AKR1B1 (0.36) AKR1B1HTR2AGRM2PIK3CAMAPK1
SCHEMBL4495729 0.89 AKR1B1 (0.38) AKR1B1FSCN1
SCHEMBL4481021 0.88 AKR1B1 (0.35) AKR1B1HDAC1HDAC6HTR2AGRM2
SCHEMBL4493645 0.88 AKR1B1 (0.35) AKR1B1TNIKHTR2AGRM2PIK3CA
SCHEMBL4494956 0.88 AKR1B1 (0.37) AKR1B1HTR2AGRM2PIK3CAMAPK1
SCHEMBL4488781 0.88 AKR1B1 (0.35) AKR1B1TNIKHDAC1HDAC6HTR2A
SCHEMBL4479511 0.87 AKR1B1 (0.36) AKR1B1TNIKHTR2AGRM2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H AKR1B1 2248/4885TNIK 564/4885HDAC1 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.